The High-Level Task Force on Covid-19 Vaccination and the HSE are to continue to work through the implications of the Oxford/AstraZeneca vaccine decision, which presents new logistical challenges in order to supply GPs around the country with the mRNA vaccines.
The mRNA vaccines are more difficult to transport, store, and administer than the Oxford/AstraZeneca vaccine, which GPs had been expecting to receive in large quantities.
The task force meets later today to consider how to ensure the vaccine roll-out plan remains on schedule. About 400,000 doses of the Oxford/AstraZeneca vaccine are expected to be delivered by the end of March.